Planegg/Martinsried, September 11, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the Baader Investment Conference 2023 in Munich to be held from September 18-21, 2023.
Corporate presentation - Baader Investment Conference 2023
https://www.baaderinvestmentconference.com/
Date and time: Monday, September 18, 2023, 2:10 pm – 2:50 pm (local time)
Location: Sofitel Munich Bayerpost in Munich
Speaker: Dr. Selwyn Ho, CEO
Members of Medigene’s management team will be available for one-on-one meetings at the event. Please contact Julia von Hummel of MC Services at Julia.vonHummel@mc-services.eu to schedule a meeting.
--- end of press release ---
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary product development and product enhancement technologies and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com
Medigene
Pamela Keck
Phone: +49 89 2000 3333 01
Email: investor@medigene.com
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
